An experimental drug-resistant HIV medicine which could potentially offer a new hope to the respective suffering patients is being tested by scientists.
The trial results of the study were set to be released during the IDWeek, the Infectious Diseases Society of America annual meeting held in collaboration with a number of three other organizations, and which takes place in New Orleans.
The study’s author, University of California, San Francisco assistant clinical professor of medicine, Doctor Jacob Lalezari declared that the experimental medicine would constitute a new chance for the often dire situation of the respective patients.
The experimental drug-resistant HIV medicine would be based on ibalizumab, and intravenous drug, and would have to be administered over every two weeks.
The respective medicine would be given to multi-drug resistant patients. As the approximated number of such sufferers is estimated to be of around 10,000, the exact cause of their immunity is not known.
The most probable causes are either the infestation with a drug-resistant virus or the failure to take on a regular basis the antiretroviral drugs commonly prescribed in controlling the disease.
The trial study of the experimental drug-resistant HIV medicine included 40 such patients, all of which had been living with the infection for an average 21 years time period.
The results of the experimental medicine were quite quick to follow as, after only seven days, a number of 83 percent of the patients registered a significant response to the drug.
A 60 percent of the patients amongst them revealed a 90 percent fall in their blood virus levels.
As the registered number is quite an important value, it would also mark the patients’ increased chance of controlling the disease.
An effective experimental medicine would also allow them to take the commonly used HIV drugs, which had previously proved ineffective, but which would now further help control the disease.
However, the results were not all positive as a 17 percent of the trial patients did not respond to the experimental drug, for reason as yet unknown, and two of the study sufferers have died.
The experimental drug-resistant HIV medicine could also present another advantage, as it could potentially stop the spreading of the virus as the treated patients would no longer transmit it.
As the study is in its final steps towards a government widespread use approval, there are still diverse variables which will have to be taken into account. Amongst them are final results of the trial, which will have to touch upon the possible side effects or adverse reactions, if any.
Another point of discussion will have to be the cost, as the biologic medications can reach quite high-cost values.
Still, the experimental drug-resistant HIV medicine could prove to be a much-needed help for the patients which are in dire need in of a new option.
Image Source: Pixabay